Bile canalicular abnormalities in the early phase of a mouse model of sclerosing cholangitis

Digestive and Liver Disease

Volumn 45, Issue 3, 2013, Pages 216-225

  Miyao, Masashi ^a   Ozeki, Munetaka ^a   Abiru, Hitoshi ^a   Manabe, Sho ^a   Kotani, Hirokazu ^a   Tsuruyama, Tatsuaki ^a   Tamaki, Keiji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

3,5 Diethoxycarbonyl 1,4 dihydrocollidine; Bile canaliculus; Cholangiopathy; Ductular reactions

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE; CELL INFILTRATION; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; ELECTRON MICROSCOPE; FEEDING; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTRAHEPATIC BILE DUCT; MALE; MICROVILLUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLEROSING CHOLANGITIS;

ANIMALS; BILE CANALICULI; BILE DUCTS, INTRAHEPATIC; CHOLANGITIS, SCLEROSING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; LIVER; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; PYRIDINES;

EID: 84875485234     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.09.007     Document Type: Article

References (41)

1. Yamamoto K., Itoshima T., Tsuji T., et al. Three-dimensional fine structure of the biliary tract: scanning electron microscopy of biliary casts. Journal of Electron Microscopy Technique 1990, 14:208-217.
2. Murakami T., Sato H., Nakatani S., et al. Biliary tract of the rat as observed by scanning electron microscopy of cast samples. Archives of Histology and Cytology 2001, 64:439-447.
3. Roskams T.A., Theise N.D., Balabaud C., et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004, 39:1739-1745.
4. Trauner M., Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiological Reviews 2003, 83:633-671.
5. Lazaridis K.N., Strazzabosco M., Larusso N.F. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004, 127:1565-1577.
6. Wu C.T., Davis P.A., Luketic V.A., et al. A review of the physiological and immunological functions of biliary epithelial cells: targets for primary biliary cirrhosis, primary sclerosing cholangitis and drug-induced ductopenias. Clinical & Developmental Immunology 2004, 11:205-213.
7. Trauner M., Fickert P., Baghdasaryan A., et al. New insights into autoimmune cholangitis through animal models. Digestive Diseases 2010, 28:99-104.
8. Trauner M., Fickert P., Halilbasic E., et al. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wiener Medizinische Wochenschrift 2008, 158:542-548.
9. Roskams T., Desmet V. Ductular reaction and its diagnostic significance. Seminars in Diagnostic Pathology 1998, 15:259-269.
10. Povero D., Busletta C., Novo E., et al. Liver fibrosis: a dynamic and potentially reversible process. Histology and Histopathology 2010, 25:1075-1091.
11. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Current Opinion in Gastroenterology 2009, 25:223-229.
12. Fickert P., Stoger U., Fuchsbichler A., et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. American Journal of Pathology 2007, 171:525-536.
13. Trauner M., Graziadei I.W. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Alimentary Pharmacology and Therapeutics 1999, 13:979-996.
14. Beuers U., Boyer J.L., Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998, 28:1449-1453.
15. Prieto J., Garcia N., Marti-Climent J.M., et al. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 1999, 117:167-172.
16. Fickert P., Zollner G., Fuchsbichler A., et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001, 121:170-183.
17. Corpechot C., Carrat F., Bonnand A.M., et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196-1199.
18. Pusl T., Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World Journal of Gastroenterology 2006, 12:3487-3495.
19. Hanada S., Strnad P., Brunt E.M., et al. The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hepatology 2008, 48:943-952.
20. Hanada S., Snider N.T., Brunt E.M., et al. Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology 2010, 138:1607-1617.
21. NIH Guide for the care and use of laboratory animals 1996, National Academy Press: National Academy of Science, Washington D.C.
22. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. Journal of Hepatology 1995, 22:696-699.
23. Gu A., Zhang Z., Zhang N., et al. Generation of human CEACAM1 transgenic mice and binding of Neisseria Opa protein to their neutrophils. PLoS ONE 2010, 5:e10067.
24. Prall F., Nollau P., Neumaier M., et al. CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. Journal of Histochemistry and Cytochemistry 1996, 44:35-41.
25. Arias I.M., Che M., Gatmaitan Z., et al. The biology of the bile canaliculus. Hepatology 1993, 17:318-329.
26. Lindros K.O. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. General Pharmacology 1997, 28:191-196.
27. Mair M., Zollner G., Schneller D., et al. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology 2010, 138:2499-2508.
28. Fickert P., Thueringer A., Moustafa T., et al. The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. Laboratory Investigation 2010, 90:844-852.
29. Polimeno L., Azzarone A., Zeng Q.H., et al. Cell proliferation and oncogene expression after bile duct ligation in the rat: evidence of a specific growth effect on bile duct cells. Hepatology 1995, 21:1070-1078.
30. Liu Z., Sakamoto T., Ezure T., et al. Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Hepatology 1998, 28:1260-1268.
31. Gray-Owen S.D., Blumberg R.S. CEACAM1: contact-dependent control of immunity. Nature Reviews Immunology 2006, 6:433-446.
32. Sundberg U., Obrink B. CEACAM1 isoforms with different cytoplasmic domains show different localization, organization and adhesive properties in polarized epithelial cells. Journal of Cell Science 2002, 115(Pt 6):1273-1284.
33. Baghdasaryan A., Claudel T., Gumhold J., et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output. Hepatology 2011, 54:1303-1312.
34. Strack I., Schulte S., Varnholt H., et al. Beta-adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Laboratory Investigation 2011, 91:252-261.
35. Fickert P., Wagner M., Marschall H.U., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130:465-481.
36. Denk G.U., Maitz S., Wimmer R., et al. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology 2010, 52:1758-1768.
37. Baghdasaryan A., Claudel T., Kosters A., et al. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010, 59:521-530.
38. Sigal M., Siebert N., Zechner D., et al. Darbepoetin-alpha inhibits the perpetuation of necro-inflammation and delays the progression of cholestatic fibrosis in mice. Laboratory Investigation 2010, 90:1447-1456.
39. Xie G., Wang X., Wang L., et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology 2012, 142:918-927. e916.
40. Phillips M.J., Azuma T., Meredith S.L., et al. Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood. Lancet 2003, 362:1112-1119.
41. Chu A.S., Russo P.A., Wells R.G. Cholangiocyte cilia are abnormal in syndromic and non-syndromic biliary atresia. Modern Pathology 2012, 25:751-757.